Articles tagged with Antibody Therapy
Researchers discovered a 'cocktail' of human antibodies that show promise in fighting severe SARS-CoV-2 infections, including Omicron variants. The study revealed how the original Moderna vaccine could prompt the body to produce these broad-spectrum antibodies.
A new class of immunotherapy has shown promising results in targeting and treating the most aggressive form of skin cancer, malignant melanoma. The study developed an IgE antibody that activates the immune response to fight cancer and slows melanoma growth in mice.
A treatment combining two antibodies against SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death. The treatment was effective against the delta variant and appeared safe, with significantly lower reports of side effects compared to a placebo.
Researchers from Lund University have designed a cocktail of modified antibodies that tag the virus to be eliminated by the immune system. The study found that combining different combinations of these antibodies can improve their function, suggesting a potent clinical effect against SARS-CoV-2 and its variants.
Researchers have developed a biodegradable skin patch that can deliver multiple doses of antibodies over several weeks, reducing pain and infection risks. The patch uses a stabilized powder of antibody, which is slowly released into the bloodstream as it degrades.
Researchers have discovered a non-invasive way to isolate tumor-reactive lymphocytes from blood, opening up new treatment options for cancer patients. This breakthrough could potentially bypass radiation therapies and harsh chemotherapy drugs, making it a more viable option for hospitals.
Researchers at Weill Cornell Medicine have identified an antibody that blocks infection by all dominant COVID-19 variants, including Omicron. The discovery could lead to new antibody-based treatments and more effective vaccines.
Researchers found that using monoclonal antibodies within two days of a COVID-19 diagnosis reduced the risk of hospitalization or death by 39% compared to those who did not receive treatment. This finding suggests that early treatment with monoclonal antibodies significantly reduced the severity of COVID-19.
Researchers analyzed 2,571 patients treated with monoclonal antibodies and found a 39% reduced risk of hospitalization or death compared to non-treated peers. The study also showed greater benefit in patients with immunocompromising conditions and those treated earlier during the pandemic.
Researchers found that immune checkpoint inhibitors increase the mobilization of overlapping tumor-reactive CD8+ T cells, leading to antitumor effects. The diverse subset of T-cell clones plays a key role in this response, with polyclonal clones exhibiting more proliferative potential and contributing to effective treatment outcomes.
Researchers have found lab-made antibodies that can strengthen the body's fight against yellow fever, a disease with no current treatment. The monoclonal antibody infusions were able to remove all signs of infection from research animals, offering potential hope for a cure.
Scientists have engineered a unique strain of probiotic bacteria to over-express a metal transporter that binds and concentrates copper, facilitating the delivery of radionuclide therapy to cancer cells. This approach targets tumors without relying on specific receptors, making it potentially effective against treatment-resistant cancers.
Researchers at La Jolla Institute for Immunology have developed a high-resolution view of the LCMV glycoprotein, revealing its structure and potential vulnerabilities. The breakthrough enables the development of an engineered antibody that can prevent LCMV disease, offering a new route to treatment.
Researchers have identified a highly conserved region of the SARS-CoV-2 spike protein that could be targeted to boost human antibody responses against any coronavirus. The discovery could aid the development of more powerful antibody drugs and vaccines against COVID-19 and emerging coronaviruses.
A team of researchers developed a novel cancer therapeutic combining antibody fragments with molecularly engineered nanoparticles, permanently eradicating gastric cancer in treated mice. The 'hit and run' drug delivery system targets HER2 proteins associated with gastric cancer.
A new study describes an optimized method for isolating and identifying nanobodies targeting SARS-CoV-2, which could lead to the development of effective therapies. The approach uses a yeast display method, reducing costs and time required for screening nanobody libraries.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
Researchers identified a type of immune cell called age-associated B cells as key drivers of lupus disease. Targeting these cells in a mouse model reduced disease progression, suggesting a potential new therapy for lupus patients.
Researchers identify 32 human monoclonal antibodies that can block SARS-CoV-2, SARS-CoV-1, and MERS-CoV coronaviruses. These antibodies target a vulnerable site on the viral spike protein, offering potential for broad protection against future pandemics.
Researchers at Arizona State University describe an innovative therapy using transient expression in tobacco plants to produce a monoclonal antibody against SARS-CoV-2. This class 4 mAb provides key advantages over existing treatments, including mutation resistance and universal protection against emerging variants.
A research group at Uppsala University has developed an artificial blood-brain barrier model that can validate the effectiveness of antibodies in reaching the brain. The model allows for the testing of antibodies without the need for animal experimentation, providing a more efficient and cost-effective alternative.
A new analysis reveals that convalescent plasma can be used to prevent hospitalizations and save lives in COVID-19 patients. Early treatment with high doses of antibodies significantly reduced hospitalization rates by up to 50%. The study provides a roadmap for using convalescent plasma as an effective therapy for future pandemics.
Researchers from Tokyo Medical and Dental University investigated the safety of anti-VEGF drug Aflibercept in a cell culture model exposed to HTLV-1. The study found that treatment did not increase pro-viral load or proliferation of RPE cells, suggesting potential for intraocular use.
A new approach to boosting protein production has been discovered, which could lead to the generation of a universal booster for protein production. The breakthrough centers on Exin21, a sequence that increases mRNA synthesis and stability and protein expression and secretion.
The addition of antioxidants to cell cultures can improve the production of monoclonal antibodies by reducing oxidative stress and increasing cell viability. This has potential benefits for therapies targeting cancer and autoimmune diseases.
A new class of SARS-CoV-2 antibodies has been shown to neutralise multiple variants of the virus, providing hope for a better antiviral medication. The antibodies work by attaching to a partially hidden part of the virus' spike protein that would be difficult for it to mutate.
Researchers from the University of Colorado found that Paxlovid significantly reduced rates of hospitalization and death among non-hospitalized patients infected with recent Omicron subvariants. The study used real-world data from 28,000 patients and suggested a benefit for Paxlovid in preventing severe disease.
Researchers highlight CD200's role in regulating immunosuppressive tumor microenvironments and propose alternative strategies for its neutralization. Unbiased genomic- and proteomic-based approaches may help clarify CD200 expression regulation across various human cancers.
A study identified an antibody candidate that blocks the protein VEGF-B, presenting a possible therapeutic option for fatty liver disease. The treatment method involves keeping fatty acids in adipose tissue to prevent liver accumulation.
Scientists at Duke-NUS Medical School and NHCS have discovered that blocking an immune-regulating protein called interleukin-11 enables damaged kidney cells to regenerate, restoring impaired kidney function. This breakthrough suggests a new approach for treating chronic kidney disease.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
Researchers at the Istituto di Ricerca in Biomedicina discovered coldspots within the coronavirus spike protein, which are remarkably conserved across variants. Antibodies targeting these coldspots showed promise in blocking virus infection and protecting against disease in preclinical models.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
Researchers from Hospital Universitario 12 de Octubre and Josep Carreras Institute create a cell therapy based on STAb cells for T-Cell Acute Lymphoblastic Leukemia (T-ALL), a rare disease with few treatment options. The new therapy offers an alternative to CAR-T therapies, which have limitations in treating this type of leukemia.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
A new analysis by Cedars-Sinai investigators shows that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups. Individuals with autoimmune diseases and solid organ transplant patients experience lower long-term antibody levels.
Researchers have discovered a new biomarker that predicts the response to CAR-T cell therapy in patients with diffuse large B cell lymphoma. The biomarker identifies differentiated T cells, which can be removed from leukemia products to improve therapy success rates.
Researchers at Integral Molecular have developed highly specific antibodies against Claudin 6, a tumor-specific protein found in multiple solid tumors. The antibodies use a single atomic contact point to derive exquisite specificity, allowing them to target cancer cells while avoiding healthy tissues.
Researchers at UCSF have developed a novel approach to prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells. By using a decoy receptor, they can capture the antibodies and take them out of circulation before they can kill the therapeutic cells.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Texas Biomed is at the forefront of developing a Sudan ebolavirus vaccine and antibody therapeutic to combat the ongoing outbreak in Uganda. The Institute has been awarded millions of dollars in contracts to run studies required for FDA approval, utilizing its BSL-4 laboratory facilities.
Researchers found that using tixagevimab-cilgavimab in blood cancer patients prevented moderate and severe COVID cases. The antibody provided protection but did not entirely prevent infection, highlighting the importance of additional safety measures.
Researchers at HKUMed identify Δ42PD-1 as a key player in suppressing killer T cells and promoting tumor growth in HCC. Targeting this protein with an antibody can inhibit tumor growth and increase functional killer T cells, offering new hope for immunotherapy against HCC
Researchers at Lund University discovered an antibody with potential to protect against Strep A infection and a rare form of binding that leads to effective immune response. The finding could explain why many Group A strep vaccines have failed.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
A study found that antibodies to common antibiotic gentamicin are associated with an increased risk of progression to type 1 diabetes in children already genetically at risk. The researchers also identified an association between the FUT2 gene and the production of these antibodies, which may be compounding risks for type 1 diabetes.
Research finds that individuals who received monoclonal antibodies before COVID vaccination exhibit a diverse antibody response, increasing the coverage provided by vaccines. This phenomenon, known as antibody feedback inhibition, is beneficial for diversifying immune responses to viruses.
Researchers at Texas A&M University engineered DARPins to block the interaction between the COVID-19 virus and host cells, significantly reducing disease progression. The nasal sprays showed effectiveness against various variants, including omicron, and could provide a lower-cost therapeutic option for those at high risk.
A research team at the University of California, Riverside has discovered the structure of a human monoclonal antibody that protects against Crimean Congo Hemorrhagic Fever virus. The study provides insights into fighting a broad range of viral strains and could lead to targeted therapeutics for infected patients.
A recent study found that the Omicron sub-lineage BQ.1.1 is resistant to all approved antibody therapies, posing a risk to high-risk patients. The researchers emphasize the importance of developing new antibody therapies specifically targeted at currently circulating and future viral variants.
A systematic review and meta-analysis of ADC clinical trials found that 91.2% of patients experienced treatment-related adverse events, with serious side effects including neutropenia, hypoesthesia, and thrombocytopenia. The study highlights the need for clinicians to address these toxicities in ADCs' use.
Researchers at Weill Cornell Medicine have identified an ultrapotent IgM antibody that neutralizes the Zika virus and prevents infection in preclinical models. The discovery could lead to the development of therapies to protect babies from birth defects caused by Zika.
Studies found that sotrovimab reduced the risk of severe covid-19 outcomes by 46% compared to molnupiravir. However, no benefit was found for common heart drugs like ARBs in a randomised controlled trial.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Researchers identified specific monkeypox mutations that contribute to its continued infectiousness. The virus is accumulating mutations where drugs and antibodies from vaccines are supposed to bind, making it smarter and more infectious.
Researchers at La Jolla Institute for Immunology have developed a new therapy for Lassa fever using a trio of rare human antibodies that can block viral infection. The therapy, called Arevirumab-3, was tested in non-human primates and proved 100% effective in treating the disease.
Researchers have isolated an effective monoclonal antibody that targets heroin, blocking its painkilling effect and overdose deaths in mice. The findings suggest that targeting heroin itself is more effective than its metabolites, paving the way for a new therapy.
Researchers developed an antibody-based treatment that targets cadherins on circulating tumor cells, eliminating them in mouse models of breast and pancreatic cancer. The therapy shows promise in preventing cancer metastasis, a leading cause of cancer-related deaths.